Frank Mottola Supernus Pharmaceuticals, Inc. (SUPN) insider trading activity

Frank Mottola is SVP, Chief Tech. Ops. Officer of SUPERNUS PHARMACEUTICALS, INC.. Currently has a direct ownership of 15,496 shares of SUPN, which is worth approximately $697,320. The most recent transaction as insider was on Sep 12, 2025, when has been sold 5,000 shares (Common Stock) at a price of $45.87 per share, resulting in proceeds of $229,350. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 15.5K

2.28% 3M change

88.98% 12M change

Total Value Held $697,320

Frank Mottola Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 12 2025	SELL Open market or private sale	$229,350 $45.87 p/Share	5,000 Reduced 24.4%	15,496 Common Stock
Sep 12 2025	BUY Exercise of conversion of derivative security	$197,000 $39.4 p/Share	5,000 Added 19.61%	20,496 Common Stock
Aug 25 2025	SELL Open market or private sale	$623,140 $44.51 p/Share	14,000 Reduced 47.46%	15,496 Common Stock
Aug 25 2025	BUY Exercise of conversion of derivative security	$181,720 $12.98 p/Share	14,000 Added 32.19%	29,496 Common Stock
Mar 07 2025	SELL Payment of exercise price or tax liability	$53,033 $39.11 p/Share	1,356 Reduced 8.21%	15,151 Common Stock
Mar 07 2025	BUY Exercise of conversion of derivative security	-	2,625 Added 13.72%	16,507 Common Stock
Mar 05 2025	SELL Payment of exercise price or tax liability	$62,530 $33.05 p/Share	1,892 Reduced 11.99%	13,882 Common Stock
Feb 26 2025	SELL Payment of exercise price or tax liability	$113,899 $39.48 p/Share	2,885 Reduced 15.46%	15,774 Common Stock
Feb 26 2025	BUY Exercise of conversion of derivative security	-	5,760 Added 24.57%	17,683 Common Stock
Feb 23 2025	BUY Grant, award, or other acquisition	-	1,875 Added 12.69%	12,899 Common Stock
Feb 22 2025	BUY Grant, award, or other acquisition	-	2,000 Added 15.36%	11,024 Common Stock
Feb 21 2025	SELL Payment of exercise price or tax liability	$21,610 $39.15 p/Share	552 Reduced 5.76%	9,024 Common Stock
Feb 21 2025	BUY Exercise of conversion of derivative security	-	1,125 Added 10.51%	9,576 Common Stock
Nov 07 2024	SELL Open market or private sale	$554,700 $36.98 p/Share	15,000 Reduced 64.66%	8,200 Common Stock
Nov 07 2024	BUY Exercise of conversion of derivative security	$136,950 $9.13 p/Share	15,000 Added 39.27%	23,200 Common Stock
Feb 28 2024	SELL Payment of exercise price or tax liability	$12,852 $27.94 p/Share	460 Reduced 5.58%	7,779 Common Stock
Feb 28 2024	BUY Exercise of conversion of derivative security	-	990 Added 10.73%	8,239 Common Stock
Feb 23 2024	SELL Payment of exercise price or tax liability	$27,229 $29.06 p/Share	937 Reduced 11.45%	7,249 Common Stock
Feb 23 2024	BUY Grant, award, or other acquisition	-	1,875 Added 18.64%	8,186 Common Stock
Feb 22 2024	SELL Payment of exercise price or tax liability	$9,359 $27.94 p/Share	335 Reduced 5.04%	6,311 Common Stock
Feb 22 2024	BUY Grant, award, or other acquisition	-	750 Added 10.14%	6,646 Common Stock
Nov 14 2023	SELL Open market or private sale	$31,224 $28.13 p/Share	1,110 Reduced 16.35%	5,681 Common Stock
Nov 14 2023	BUY Exercise of conversion of derivative security	$18,480 $9.24 p/Share	2,000 Added 22.75%	6,791 Common Stock
Mar 14 2023	SELL Open market or private sale	$172,032 $35.99 p/Share	4,780 Reduced 50.23%	4,737 Common Stock
Feb 22 2023	BUY Grant, award, or other acquisition	-	750 Added 7.3%	9,517 Common Stock

Frank Mottola

SVP, Chief Tech. Ops. Officer

Rockville, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SUPN shares.

Notify only if

Value

Insider Trading

Get notified when an Supernus Pharmaceuticals, Inc. insider buys or sells SUPN shares.

Notify only if

Operation

Value

Type

News

Receive news related to SUPERNUS PHARMACEUTICALS, INC.

Track Activities on SUPN

Account